ロード中...
Re-Evaluating Progression in an Era of Progress: A Review of First- and Second-Line Treatment Options in Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer
The advent of crizotinib, the first small molecule inhibitor against anaplastic lymphoma kinase (ALK), has led to impressive advances in the care of patients with advanced ALK-rearranged non-small cell lung cancer. The development of second-generation ALK inhibitors, starting with the recent U.S. Fo...
保存先:
| 出版年: | Oncologist |
|---|---|
| 主要な著者: | , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
AlphaMed Press
2016
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4912362/ https://ncbi.nlm.nih.gov/pubmed/27053502 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2015-0396 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|